Inhibition of necroptosis has been suggested as a therapeutic strategy in diseases such as ALS and AD where RIPK1 activation has been reported (Li et al., 2012; Kaiser et al., 2014; Re et al., 2014; Vanden Berghe et al., 2015; Ito et al., 2016; Caccamo et al., 2017; Ofengeim et al., 2017; Degterev et al., 2019). Here, RIPK1 is linked to Alzheimer disease.